Kidswell Bio Corporation

Business Details

Operates two businesses: the biosimilar business (supply of API and related materials for four launched products) and the cell therapy business (development of regenerative medicine products utilizing deciduous tooth pulp stem cells, SQ-SHED). The company employs a "stability and growth compatibility" model, reinvesting stable earnings from the biosimilar business into research and development investment for the cell therapy business. Major customers are Senju Pharmaceutical (net sales of ¥3,468 million in the current period, 52.6% of net sales) and Mochida Pharmaceutical (¥2,240 million, 34.0%). The company has built a virtual R&D structure in which all manufacturing is outsourced to CDMOs.

Recent Overview

Net sales increased 29.7% year on year to ¥6,589 million, but the company fell into a consolidated operating loss due to a sharp rise in R&D expenses and an inventory write-off, among other factors

Full-year net sales for FY2026 (ending March 2026) reached ¥6,589 million (up 29.7% year on year), achieving an increase in revenue. This was driven by the full-year contribution of supply price revisions and the switch to products with reduced manufacturing costs, while R&D expenses surged to ¥1,119 million (up 46.1% year on year). In addition, non-operating expenses recorded in the interim period, including a ¥125 million inventory write-off related to biosimilar API and related materials and ¥75 million in syndicated loan arrangement fees, resulted in an operating loss of ¥138 million and an ordinary loss of ¥374 million. For the following fiscal year (FY2027, ending March 2027), the company expects to return to consolidated operating profitability due to the full-year contribution of supply price revisions and the switch to products with reduced manufacturing costs, disclosing a range forecast of net sales of ¥5,000 million to ¥6,000 million and operating income of ¥100 million to ¥600 million. In the cell therapy business, pipeline development advanced significantly, including the announcement of interim analysis results from the cerebral palsy clinical research, completion of a Pre-IND Meeting with the US FDA, and progress in preparations for domestic clinical trials with Mochida Pharmaceutical.

Key Products

Growth Drivers

• Full-year contribution of supply price revisions and the switch to products with reduced manufacturing costs in the following fiscal year is expected to improve margins in the biosimilar business
• Stable securing of API and related material deliveries due to continued solid market demand for GBS-007 (Ranibizumab) and GBS-010 (Pegfilgrastim)
• Stable maintenance of market share due to the achievement of a switching rate exceeding 80% from originator products for GBS-001 and GBS-011
• Enhancement of pipeline value through progress in preparations for domestic clinical trials with Mochida Pharmaceutical for the cell therapy business (GCT-103) and preparations for a US IND application
• Medium- to long-term expansion of the domestic biosimilar manufacturing and revenue base through the establishment of the Alfenax Biologics joint venture and the start of manufacturing facility construction
• Diversification of future revenue sources through progress in cell line construction for multiple candidate products under new biosimilar joint development (three-company collaboration with Alfresa Holdings, Chiome, and MBI)
• Strengthened financial base and stabilized cash flow through a syndicated loan totaling ¥2,500 million (arranged by Mizuho Bank), concluded in November 2025
• Expansion of SQ-SHED indications through AMED adoption (hypoganglionosis) and joint research on infertility with UK-based LYMPHOGENiX, among others

Risks

• Changes in the competitive environment and impact on future sales trends due to the listing of drug prices and launch of sales of aflibercept biosimilars and bio-AGs (authorized generics) in the GBS-007 market
• Risk of increased manufacturing costs due to overseas price inflation and yen depreciation, as all biosimilar API manufacturing is outsourced to overseas CDMOs (with a time lag between revenue recognition timing and payment timing)
• A material event related to going concern assumptions: the possibility of temporary negative period income due to continued R&D investment (although it has been determined that no material uncertainty exists)
• The cell therapy business is in a stage of upfront R&D investment, carrying risks of delays or failures in clinical development and risk of the need for additional fundraising
• High customer concentration risk, as net sales in the biosimilar business are highly concentrated among two companies, Senju Pharmaceutical (52.6%) and Mochida Pharmaceutical (34.0%)
• Risk that continued annual drug price reductions under Japan's drug pricing system will persistently pressure profit margins
• Operational risks in the manufacturing process, exemplified by the inventory write-off loss (¥125 million recorded in the current period), could be a factor causing downside deviation from earnings forecasts
• The forecast for the following fiscal year is disclosed as a range (net sales of ¥5,000 million to ¥6,000 million, operating income of ¥100 million to ¥600 million), reflecting high uncertainty regarding changes in the competitive environment and clinical development expenses